Employees: 03 (2023.0)Legal category: 5485Size: PMECreation date: 2007-03-02 (19 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: MISSILLAC (44780), Loire-Atlantique
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
PHARMACIE DE LA BRETESCHE : revenue, balance sheet and financial ratios
PHARMACIE DE LA BRETESCHE is a French company
founded 19 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in MISSILLAC (44780),
this company of category PME
shows in 2023 a revenue of 3.2 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - PHARMACIE DE LA BRETESCHE (SIREN 494988272)
Indicator
2025
2024
2023
2022
2021
2020
2019
2018
2017
Revenue
N/C
N/C
3 215 990 €
N/C
N/C
N/C
N/C
N/C
N/C
Net income
123 369 €
121 970 €
129 280 €
189 856 €
156 365 €
122 390 €
119 893 €
187 484 €
184 794 €
EBITDA
N/C
N/C
227 488 €
N/C
N/C
N/C
N/C
N/C
N/C
Net margin
N/C
N/C
4.0%
N/C
N/C
N/C
N/C
N/C
N/C
Revenue and income statement
In 2025, PHARMACIE DE LA BRETESCHE generates positive net income of 123 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2017-2025: 185 k€ -> 123 k€.
Net income (2025)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
123 369 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 43%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 59%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2025)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
42.736%
Financial autonomy (2025)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
58.853%
Asset age ratio (2025)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Solvency indicators evolution PHARMACIE DE LA BRETESCHE
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2017
2018
2019
2020
2021
2022
2023
2024
2025
Debt ratio
172.167
123.446
160.137
130.481
106.711
83.269
66.003
49.238
42.736
Financial autonomy
32.814
40.948
34.435
39.209
42.904
45.776
49.642
57.026
58.853
Repayment capacity
None
None
None
None
None
None
4.292
None
None
Cash flow / Revenue
None%
None%
None%
None%
None%
None%
5.83%
None%
None%
Sector positioning
Debt ratio
42.742025
2023
2024
2025
Q1: 13.71
Med: 49.76
Q3: 129.07
Good
In 2025, the debt ratio of PHARMACIE DE LA BRETESCHE (42.74) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.
Financial autonomy
58.85%2025
2023
2024
2025
Q1: 33.42%
Med: 53.71%
Q3: 72.08%
Good+6 pts over 3 years
In 2025, the financial autonomy of PHARMACIE DE LA BRETESCHE (58.9%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
Repayment capacity
4.29 years2023
2023
Q1: 0.95 years
Med: 3.58 years
Q3: 7.48 years
Average
In 2023, the repayment capacity of PHARMACIE DE LA BRETESCHE (4.29) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 151.69. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2025)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
151.691
Liquidity indicators evolution PHARMACIE DE LA BRETESCHE
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2017
2018
2019
2020
2021
2022
2023
2024
2025
Liquidity ratio
236.568
301.394
159.403
197.633
198.006
177.72
149.582
155.145
151.691
Interest coverage
None
None
None
None
None
None
4.701
None
None
Sector positioning
Liquidity ratio
151.692025
2023
2024
2025
Q1: 131.03
Med: 182.29
Q3: 258.7
Average
In 2025, the liquidity ratio of PHARMACIE DE LA BRETESCHE (151.69) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
Interest coverage
4.7x2023
2023
Q1: 0.38x
Med: 2.71x
Q3: 6.47x
Good
In 2023, the interest coverage of PHARMACIE DE LA BRETESCHE (4.7x) ranks above the median of the sector. This ratio indicates how many times operating income covers interest expenses. This comfortable position offers an appreciable safety margin.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
Operating WCR (2025)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
0 €
Customer credit (2025)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
0 j
Supplier credit (2025)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
0 j
Inventory turnover (2025)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
0 j
WCR and payment terms evolution PHARMACIE DE LA BRETESCHE
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2017
2018
2019
2020
2021
2022
2023
2024
2025
Operating WCR
0 €
0 €
0 €
0 €
0 €
0 €
193 892 €
0 €
0 €
Inventory turnover (days)
0
0
0
0
0
0
22
0
0
Customer payment term (days)
124
100
146
145
112
120
3
0
0
Supplier payment term (days)
936
693
764
750
735
1092
47
0
0
Positioning of PHARMACIE DE LA BRETESCHE in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 277 transactions of similar company sales
in 2025,
the value of PHARMACIE DE LA BRETESCHE is estimated at
1 959 731 €
(range 1 329 882€ - 3 075 088€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2025
277 transactions
1329k€1959k€3075k€
1 959 731 €Range: 1 329 882€ - 3 075 088€
NAF 5 année 2025
Valuation method used
Net Income Multiple
123 369 €
×
15.9x
=1 959 731 €
Range: 1 329 883€ - 3 075 088€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare PHARMACIE DE LA BRETESCHE with other companies in the same sector:
Frequently asked questions about PHARMACIE DE LA BRETESCHE
What is the revenue of PHARMACIE DE LA BRETESCHE ?
The revenue of PHARMACIE DE LA BRETESCHE in 2023 is 3.2 M€.
Is PHARMACIE DE LA BRETESCHE profitable?
Yes, PHARMACIE DE LA BRETESCHE generated a net profit of 123 k€ in 2025.
Where is the headquarters of PHARMACIE DE LA BRETESCHE ?
The headquarters of PHARMACIE DE LA BRETESCHE is located in MISSILLAC (44780), in the department Loire-Atlantique.
Where to find the tax return of PHARMACIE DE LA BRETESCHE ?
The tax return of PHARMACIE DE LA BRETESCHE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does PHARMACIE DE LA BRETESCHE operate?
PHARMACIE DE LA BRETESCHE operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart